XFOR nears Phase III mavorixafor enrollment completion
XFOR says its Phase III trial for chronic neutropenia is on track to complete enrollment by year-end. Top-line data is expected in early 2028, with a new G-CSF titration study planned and commercial launch targeted for late 2028 or early 2029.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.